Cure My Disease

Don't miss your cure!

 Log in / Sign up

New platform seeks to break down barriers for underserved cancer patients in clinical trials

NCT ID NCT04630431

Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at why minority cancer patients often don't take part in clinical trials. Researchers surveyed patients about their understanding and attitudes, then tested an educational video and booklet to see if it boosted enrollment. The goal was to create a personalized platform that helps underserved patients overcome barriers to participation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Educational intervention (video and booklet) and patient navigation
What this could lead to
If successful, this could lead to a personalized educational tool that helps more minority cancer patients understand and join clinical trials.
What could go wrong
The study was terminated early, so results may be limited. It focuses on understanding preferences rather than testing a treatment, so direct health benefits are not expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

590 people

The number who actually took part.

Started

Oct 2019

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PART I: Subjects must be adults with age \>= 18 years at the time of study entry * PART I: Subjects with any cancer diagnosis may be included * PART I: Subjects must be identified as new patients to hematology oncology at the treating site * PART I: Subjects must be willing to provide informed consent for the study * PART II: Subjects must be adults with age \>= 18 years at the time of study entry * PART II: Subjects with any cancer diagnosis may be included * PART II: Subjects must be identified as new patients to hematology oncology at the treating site * PART II: Subjects must be willing to provide informed consent for the study Exclusion Criteria: * PART I: Patients reported to have an estimated life-expectancy of \< 6 months, as assessed by their clinician * PART I: Patients not willing to complete the Clinical Trials Study survey * PART II: Patients reported to have an estimated life-expectancy of \< 6 months, as assessed by their clinician * PART II: Patients not willing to complete the education intervention or continued follow up for at least 2 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematopoietic and lymphoid cell neoplasm are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematopoietic and lymphoid cell neoplasm Malignant solid neoplasm

Contacts and locations

Locations

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Mayo Clinic in Florida

    Jacksonville, Florida, 32224-9980, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.